Bavencio (avelumab) vs Vegzelma (bevacizumab-adcd)
Bavencio (avelumab) vs Vegzelma (bevacizumab-adcd)
Bavencio (avelumab) is a PD-L1 blocking antibody used primarily for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma, working by enhancing the body's immune response against cancer cells. Vegzelma (bevacizumab-adcd) is a biosimilar to Avastin (bevacizumab) and is designed to inhibit vascular endothelial growth factor (VEGF), thereby impeding the growth of blood vessels that supply tumors, and is used in various cancers, including colorectal, lung, glioblastoma, kidney, and cervical cancers. When deciding between Bavencio and Vegzelma, it is crucial to consider the specific type of cancer being treated, the mechanism of action of each medication, and the patient's overall health profile, as each drug is tailored to different indications and has a unique impact on the immune system and tumor growth.
Difference between Bavencio and Vegzelma
| Metric | Bavencio (avelumab) | Vegzelma (bevacizumab-adcd) |
|---|---|---|
| Generic name | Avelumab | Bevacizumab-adcd |
| Indications | Merkel cell carcinoma, urothelial carcinoma, renal cell carcinoma | Metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer |
| Mechanism of action | PD-L1 inhibitor, immune checkpoint inhibitor | VEGF inhibitor, angiogenesis inhibitor |
| Brand names | Bavencio | Vegzelma |
| Administrative route | Intravenous infusion | Intravenous infusion |
| Side effects | Fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reactions, rash, decreased appetite | Hypertension, proteinuria, hemorrhage, arterial thromboembolism, venous thromboembolism, gastrointestinal perforation, wound healing complications |
| Contraindications | Severe hypersensitivity to avelumab or any of its components | Severe hypersensitivity to bevacizumab, bevacizumab-containing products, or any of its components |
| Drug class | Monoclonal antibody, PD-L1 inhibitor | Monoclonal antibody, VEGF inhibitor |
| Manufacturer | EMD Serono, Pfizer | Celltrion Healthcare |
Efficacy
Bavencio (Avelumab) Efficacy in Kidney Cancer
Bavencio, known generically as avelumab, is a PD-L1 blocking antibody that has shown efficacy in the treatment of kidney cancer, specifically advanced renal cell carcinoma (RCC). Avelumab works by inhibiting the interaction between PD-1/PD-L1 and is designed to impact both tumor cells and the tumor microenvironment. In the treatment of kidney cancer, Bavencio is often used in combination with axitinib, a tyrosine kinase inhibitor. This combination has been approved based on the results of clinical trials that demonstrated a significant improvement in progression-free survival compared to sunitinib in patients with advanced RCC.
The efficacy of Bavencio in combination with axitinib was evaluated in a phase III study, JAVELIN Renal 101, which included patients with untreated advanced RCC. The results showed that the combination significantly improved median progression-free survival in patients with PD-L1 positive tumors compared to sunitinib, a standard treatment. Moreover, the combination therapy also benefited the overall population regardless of PD-L1 expression, suggesting a broad potential for this treatment regimen in advanced RCC.
Vegzelma (Bevacizumab-adcd) Efficacy in Kidney Cancer
Vegzelma, with the generic name bevacizumab-adcd, is a biosimilar to the original bevacizumab product and is designed to inhibit vascular endothelial growth factor (VEGF). By blocking the VEGF pathway, Vegzelma reduces the formation of blood vessels that supply tumors, thereby inhibiting tumor growth. Bevacizumab, and consequently its biosimilar Vegzelma, has been used in the treatment of advanced RCC in combination with interferon alpha. Clinical studies have demonstrated that this combination improves overall survival and progression-free survival in patients with metastatic RCC compared to interferon alpha alone.
The approval of Vegzelma as a biosimilar was based on a comprehensive data package that demonstrated its similarity to the reference product bevacizumab in terms of safety, purity, and potency. While Vegzelma itself may not have been independently studied in large clinical trials for kidney cancer, the expectation is that its efficacy and safety profile will closely match that of the original bevacizumab product, which has a well-established role in the treatment of advanced RCC.
Regulatory Agency Approvals
Bavencio
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Therapeutic Goods Administration (TGA), Australia
Vegzelma
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Bavencio or Vegzelma today
If Bavencio or Vegzelma are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us